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Hemodialysis and red cell cation transport in uremia: Role of mem-
brane free fatty acids. Active and facilitated cation transport in eryth-
rocytes of uremic patients may be improved acutely by hemodialysis,
although the mechanisms remain unknown. As nonesterifled fatty acids
(NEFA) can affect Na pump activity in vitro, changes in plasma and
red cell membrane NEFA content following a single hemodialysis
procedure were examined and compared with acute changes in eryth-
rocyte cation flux rates in 34 hemodialysis patients. In nonsodium-
loaded cells, small changes in Na pump flux with dialysis did correlate
with changes in intracellular Na content (r = 0.59; N 17; P < 0.01).
On average, neither maximal Na pump activity nor Na/Li counter-
transport flux improved with dialysis, but Na/K/Cl cotransport
rates rose 25% post-dialysis (P < 0.02). Plasma NEFA levels rose 87%
following hemodialysis but erythrocyte membrane NEFA content de-
clined by 23% (P < 0.001). Importantly, 24 of the 34 subjects studied
had a decrease in erythrocyte membrane NEFA content of greater than
10%, and in these patients, the fall in membrane NEFA correlated with
an increase in ouabain-sensitive Na efflux (r = 0.564; P < 0.01). The
effects of hemodialysis on both erythrocyte NEFA content and Na
pump flux could be reproduced by incubating pre-dialysis cells in fatty
acid-free albumin. We conclude that acute changes in membrane NEFA
may modulate active cation transport in uremic erythrocytes.
Severe chronic renal insufficiency (CRF) and the uremic
syndrome are characterized by a number of biochemical and
physiologic abnormalities, including defects in transmembrane
cation transport [1]. Although most investigators have exam-
ined active and facilitated cation transport pathways in the
erythrocyte [2—91, observations in several other tissues, includ-
ing leukocytes [101, skeletal muscle [11, 12], and adipose tissue
[12] support the hypothesis that a generalized alteration in
cation transport pathways exists in uremia. The activity of the
Na pump has been the most intensively studied ion transport
system. Controversy remains as to whether a majority of
uremic patients exhibit decreased Na pump activity and/or
number, but there appears to be a consensus that at least a
subset of patients have reduced ouabain-sensitive cation flux
rates, a defect that may be ameliorated acutely by hemodialysis
[2, 4]. Several recent reports have also described a decrease in
furosemide-sensitive Na/K/C1 cotransport in uremic eryth-
Received for publication December 14, 1987
and in revised form June 24, 1988
© 1989 by the International Society of Nephrology
rocytes [7, 13], a defect we have also found in adipocytes and
skeletal muscle of uremic rats [12].
Despite the considerable evidence for abnormal cation trans-
port in uremic patients and in experimental animals with CRF,
the mechanism for these changes remains unknown. Plasma
factors, including uremic toxins and possibly endogenous Na
pump inhibitors, have been implicated since the early experi-
ments of Cole, Balfe and Welt [2] who reported that uremic
serum could transfer the defect in Na pump activity to normal
erythrocytes, abnormalities that have been confirmed by some
[4], but not all, investigators [13]. There have also been many
reports of factors with endogenous digitalis-like activity in the
plasma of patients with uremia [14—16].
Recently, several laboratories [17, 18, 19], including our own
[20, 21], have identified polar lipids in plasma, predominantly
nonesterified fatty acids (NEFA) and certain lysophospholip-
ids, as potential endogenous modulators of the Na pump. We
found that NEFA and other polar lipids could reversibly inhibit
NaK-ATPase activity in vitro and inhibit ouabain binding to the
cardiac glycoside binding site on NaK-ATPase. However, it has
remained unclear whether polar lipid compounds in plasma
could ever affect Na pump activity or other ion transporters in
a physiologically important manner in vivo. Since abnormalities
both of lipid metabolism [22] and of plasma protein binding of
NEFA occur in uremia [23], we wished to determine whether
the changes in plasma NEFA levels that occur acutely with
hemodialysis are paralleled by changes in red cell membrane
NEFA content, and whether altering membrane NEFA levels
could be correlated with changes in both active and facilitated
transmembrane cation transport.
Methods
Preparation of red cell membranes
Blood was drawn into chilled heparinized tubes and kept on
ice until processed; this was always less than 45 minutes. Whole
blood was centrifuged, the buffy coat was removed, and the
plasma was immediately extracted with organic solvents. Four
ml of packed RBCs were resuspended in a preservation solution
containing 140 mrvt KCI, 10 mrst NaCI, 25 ifiM KPO4, 10 mM
Tris-Mops (pH 7.4 at 4°C) and 1 mrt MgCI2 (hematocrit 50%)
and kept at 4°C until used for cation flux and [3H]ouabain
binding experiments. Another aliquot of cells was immediately
washed four times in a choline wash solution (CWS: 149 mM
choline Cl, 1 mitt MgCl2, 0.1 M ms-Mops, pH 7.4, 4°C) and
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resuspended in a 1:50 dilution of 0.02% Acationox (American
Scientific Products, Boston, Massachusetts, USA) to measure
hematocrit and intracellular electrolytes. To determine the
membrane NEFA content, 2 ml of RBCs were resuspended in
an isotonic Tris buffer (172 mr,t Tris-CI, pH 7.6 at 4°C, 310
mOsm) and washed twice to remove plasma. Five ml aliquots of
a 50% suspension of washed RBCs were transferred to 50 ml
polycarbonate tubes containing 40 ml of a 11.1 mrs Tris hypo-
tonic buffer (20 mOsm, pH 7.6 at 4°C). The tubes were vortexed
vigorously, centrifuged at 20,000 g for 30 minutes at 4°C, and
the supernatant was discarded. RBC membranes were resus-
pended inS ml of a sucrose buffer (0.25 Msucrose, 1 mM EDTA,
20 mt,t Tris-Cl, pH 7.4 at 4°C). A 100 tl aliquot was added to 100
M1 of 0.05 M NaOH in 1% (vol/vol) sodium dodecyl sulfate,
vortexed, and frozen at —20°C for later protein determination.
Two 1 ml aliquots were immediately prepared for determination
of red cell membrane NEFA; the remainder was stored at
—20°C.
Determination of plasma and red cell membrane NEFA
content
One ml aliquots of RBC ghost membranes in sucrose buffer
were heated to 70°C for 15 minutes in glass centrifuge tubes
under a constant stream of N2 in order to inactivate phospho-
lipases. This step was always performed immediately following
phlebotomy and preparation of erythrocyte ghosts, with care
taken to keep all buffers cold. Twenty-five nmoles of an internal
standard (C17.0; heptadecanoic acid, Sigma Chemical Co., St.
Louis, Missouri, USA) were added, the tubes were vortexed
and then 1 ml methanol was added and mixed by vortexing for
15 seconds. Three ml of chloroform/BHT (butylated hydroxy-
toluene, 50 mg/liter) solution were added, vortexed for one
minute, centrifuged at 2,000 g for five minutes, and the organic
layer was transferred to a second conical glass centrifuge tube.
The aqueous layer was washed with a 1:3 mixture of methanol!
chloroform, and the organic layers from the first and second
wash were combined and dried under N2. The extracted red cell
membrane lipid mixture was redissolved in 1 ml of chloroform,
and 200 .d aliquots were placed in 5 ml glass tubes to which an
additional 300 d of chloroform were added. Triplicate 500 d
aliquots were added to preparative low pressure aminopropyl-
bonded phase columns (Bond-Elut, Analytichem International,
Harbor City, California), to separate NEFA from other polar
and neutral lipids according to the technique of Kaluzny et al
[24]. The columns were eluted with 4 ml of a 2:1 mixture of
chloroform:2-propanol to remove neutral lipids, and then 4 ml
of 2% acetic acid in diethyl ether to remove NEFA. This second
eluate was dried under N2 and redissolved in 1 ml of chloro-
form/BHT and stored at —20°C until derivatization. This tech-
nique for separating complex lipid mixtures yielded recoveries
of radiolabelled lipids of >95%, in agreement with the report of
Kaluzny et al [24] and Kelly et al [25].
Plasma samples were kept on ice until lipids were extracted.
This was done within 45 minutes of venipuncture. Two hundred
and fifty pi aliquots of plasma were added to 250 1.d of water
containing 20 nmoles of hepatadecanoic acid. This was ex-
tracted twice in methanol/chloroform (1:3, vol!vol) containing
50 mg!ml BHT. The combined organic phases were dried under
N2, reconstituted in 1 ml chloroform, and applied to Bond Elut
columns to separate NEFA as described above [25]. Following
the separation of NEFA from other plasma lipids, they were
stored in chloroform!BHT at —20°C until assayed.
NEFA from erythrocyte ghost membranes and plasma were
quantitated using a modification [25] of the technique of Tsu-
chiya et al [26, 27]. Frozen lipid samples were dried under N2,
reconstituted in I ml of acetone, and derivatized with the
fluorescent reagent, 4-bromomethyl, 7-acetoxy coumarin (Br-
Mac), as described previously [25]. Denvatized NEFA were
separated by reverse phase HPLC, with post-column alkaline
hydrolysis of Br-Mac, while Br-Mac fluorescence was moni-
tored at 365 nm excitation and 460 nm emission. The coefficient
of variation was less than 5%, with at least 10 pmol of each
NEFA injected for plasma samples, and less than 9% for red
cell ghost membrane samples; the limit of detection was ap-
proximately 50 fmoles. All samples were run in duplicate or
triplicate. Red cell ghost NEFA were standardized to the
membrane protein measured by the Lowry technique [281, with
bovine serum albumin (Sigma) as a standard. All solvents used
in the lipid extractions, preparative chromatography, and
HPLC were HPLC grade and obtained from Fisher Scientific
(Medford, Massachusetts, USA).
Red cell cation flux measurements
RBCs suspended in the preservation buffer were used in a
cation flux assay within 24 hours of venipuncture. The RBC
electrolyte content was always determined within two hours of
venipuncture. 86Rb influx into, or Na efflux from, erythrocytes
was measured using either fresh cells RBCs or RBCs loaded
with Na to measure the maXof the Na pump (loaded cells).
Sodium efflux. Sodium effiux into choline-containing media
and intracellular electrolyte content were measured as previ-
ously described [29, 30]. For assays at the Vmax of the Na
pump, RBCs were loaded to contain 50 mmol!liter cell of Nat,
as previously described [31]. The nystatin loading solution
contained 70 mi KCI, 70 m NaCI and 50 m sucrose.
Ouabain-sensitive Na flux was measured by incubating the
cells in 10 mM KC1 in choline media [31]. For measurement of
lithium-sodium countertransport, RBCs were loaded with 10
mM LiC1 and 130 mri KCI in the presence of nystatin, and the
efflux of lithium into a choline and Na medium was measured,
as previously described [29]. Following Li loading, the intra-
cellular Li concentration was 6.7 0.5 mmol!liter pre-dialysis
and 6.9 0.4 mmollliter post-dialysis. Nystatin was removed
by incubating loaded cells in a washing solution containing 0.1
g/l® ml albumin (bovine, fraction V, Sigma) of similar ionic
composition as the loading solution. Na/K!Cl cotransport
was determined by furosemide-sensitive Na efflux into choline
media containing ouabain, as previously described [30].
In 20 patients from Group 1, ouabain-sensitive Na effiux
rates were also determined in aliquots of pre-dialysis red cells
that had been pre-incubated in delipidated albumin. Following
Na loading of cells and removal of the nystatin using Cohn
fraction V, non-delipidated, bovine serum albumin, an aliquot
of cells was resuspended in buffer containing 70 m NaCI, 70
mM KC1, 10 m Tris-Mops (pH 7.4 at 37°C), 50 mri sucrose, 0.1
mM KPOI, 10 mM glucose, 1.0 mg/ml fatty acid free bovine
serum albumin (Sigma #A7030), and incubated at 37°C for 30
minutes. These cells were then washed with CWS five times
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and used in parallel determinations of cation flux rates,
[3H]ouabain binding, and RBC membrane NEFA content.
86Rh influx. Because the albumin used to remove the iono-
phore, nystatin, from RBC membranes after loading with Na4
could influence cation flux rate by removing NEFA from the
membrane (Results), a different procedure was used. Because
treatment with 2,5-p-chloro-mercuribenzene sulfonate
(PCMBS) has been used extensively to study Na4 pump
kinetics [32], we used this procedure in parallel incubations in
cells obtained from 10 hemodialysis patients. Rb influx into
fresh RBCs was determined by incubating red cells in 150 mM
NaCl, 1 mti MgCl2, 10 mtt Tris-Mops (pH 7.4 at 37°C), 10 mM
glucose, and 4mM KCI with 100 1LCi 86Rb, with and without 0.1
mM ouabain or 0.1 ms'i ouabain and 1 mrvi furosemide. Triplicate
samples were obtained after five minute and 25 minute incuba-
tions at 37°C in a shaking water bath. The RBCs were washed
three times with cold influx media, and then the cell pellet was
lysed with 0.02% Acationox and centrifuged. Aliquots of the
cell lysate were used for counting 86Rb and optical density of
hemoglobin for determination of the red cell volume. 86Rb was
determined by gamma counting. The specific activity of 86Rb/
K4 was used to determine the influx in mmol/liter celllhr.
Red cell [3HJouabain binding
Aliquots of packed RBCs were resuspended in a buffer
containing 150 mM NaCI, 1 mrvi MgCl2, and 10 m Na4
phosphate (pH 7.4 at 37°C) and washed twice. RBCs (0.5 ml)
resuspended in this buffer (25% hematocrit) were added to
tubes containing [3H]ouabain (20 Cilmmol, New England Nu-
clear, Bedford, Massachusetts, USA; l0 M final concentra-
tion) in 0.5 ml of buffer with or without 0.1 m unlabelled
ouabain and incubated for one hour at 37°C. RBC number was
determined using a Coulter Counter (Coulter Electronics, Hai-
leigh, Florida, USA). Following the incubation, the cells were
washed twice in 2 ml of iced Na phosphate buffer solution (pH
7.4 at 4°C), and 0.2 ml of 10% perchloric acid were added to
extract bound [3H]ouabain. Radioactivity was determined by
scintillation counting with correction for quenching using an
external standard.
Patients
Subjects participating in this study were stable hemodialysis
patients who were not receiving digitalis and had not received a
blood transfusion within two weeks of the study. All patients
were receiving three dialysis treatments per week. Approxi-
mately 60% were dialyzed with a bicarbonate containing bath
(in mmol/liter: Na 135, Ca 3, Mg 0.75, Cl 104.8, bicarbonate 35)
and 40% with an acetate containing bath (in mmol/liter: Na
136.5, Ca 3, Mg 0.75, Cl 103.1, acetate 39.2). The concentra-
tions of dextrose and K4 were varied according to each
patient's clinical condition and plasma K4 level. Erythrocytes
from 28 age-matched ambulatory patients with normal renal
function were also studied to determine [1Hjouabain binding
and intracellular Na content. This study was approved by the
Human Subjects Committee of the Brigham and Women's
Hospital.
Statistics
Data are presented as the mean SCM and statistical evalu-
ation was based on paired observations using the Student's
Table 1. Clinical characteristics of the dialysis patients
Group I
Na-/oaded cells
Group 2
fresh cells
Number of patients 34 17
Age yr 65.7 3.7 61.1 4.9
Sex 20W/14M II W/6M
Weight change with 1.6 0.18 1.6 0.35
dialysis kg
Serum Na mmol/liter 135.0 0.6 133.4 1.1
Serum K mmol/liter 5.1 0.2 4.9 0.3
Serum Cl ,nmol/!iter 99.8 1.0 98.7 1.6
Serum HCO1 mmol/!iier 20.0 0.6 20.7 1.0
BUN mg/dl 72.4 4.0 84.6 9.8
Serum Cr ,ng/dl 8.7 0.4 10.0 1.1
Albuming/dl 3.3±0.1 3.2±0.1
Values are mean SCM.
Table 2. The effects of hemodialysis on intracellular Na4 and K4
content of fresh cells
Pre-dialysis Post-dialysis P
Group I
Na 9.2 0.5 9.4 0.5 NS
K4 101.9 1.7 102.6 1.7 NS
Group 2
Na4 9.4 0.7 9.9 0.9 NS
K4 99.4 1.8 100.8 2.3 NS
Values are mean 5EM in mmol/liter cell prior to Na4 loading with
nystatin and/or PCMBS (Methods) for 34 patients in Group I and 17
patients in Group 2.
t-test, unless otherwise noted; the null hypothesis was rejected
if P <0.05.
Results
The clinical characteristics of the 51 patients studied are
shown in Table 1. Maximal rates of Na4 transport in Na4-
loaded erythrocytes, as well as plasma and cell membrane
NEFA content were studied in 34 hemodialysis patients (Group
1, Table 1). In a second group of 14 hemodialysis patients
(Group 2, Table 1), 86Rb influx into fresh cells was studied to
determine whether acute changes in intracellular Na4 content
could account for some of the changes in active Na transport
that occur with dialysis. Aside from the higher percentage of
women in Group 2, the two study populations were not different
in other clinical parameters. Fourteen patients in Group 1 were
Black and four were Hispanics, compared to eight and two in
Group 2, respectively. There was no apparent correlation
between race and any cation flux parameter. There was also no
correlation between the composition of the dialysis bath (ace-
tate or bicarbonate) and changes in either plasma membrane
NEFA levels or cation flux rates.
Effect of dialysis on cation transport
There was no significant change in intracellular Na4 or K
with hemodialysis in Group 1 patients or Group 2 patients
(Table 2). In 10 of 34 Group I patients, erythrocyte cation
transport pre- and post-dialysis were assessed by measuring
86Rb influx, as well as Na4 efflux. In these patients, the two
methods commonly used for Na4 loading, PCMBS and nysta-
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Table 3. Changes in red cell cation transport and in [3H]ouabain
binding during hemodialysis
____________
Pre- Post-
dialysis dialysis % Change P
4.10 0.24 4.31 0.27 6.9 5.9 NS
0.56 0.06 0.69 0.07 25.0 9.9 <0.02
0.39 0.04 0.41 0.04 12.3 10.0 NS
320 36 321 21 -3.l 8.4 NS
1.72 0.12 1.68 0.14 —4.5 6.4 NS
328 19 316 20 —2.2 4.7 NS
Values are mean SEM from 34 patients in Group 1 (Na/Li
countertransport was studied in 12) and 17 patients in Group 2. All ion
fluxes are expressed in mmollliter cell per hr and ouabain-binding as
sites per cell.
a Ouabain-sensitive Na efflux (Group 1) or ouabain-sensitive 86Rb
influx (Group 2)
b Furosemide-sensitive Na efflux
Li efflux stimulated by external Na. In Group 2, Na pump
activity was determined as ouabain-sensitive 86Rb influx into fresh cells.
tin, were compared to assess whether the nystatin method, in
which the ionophore is removed with albumin, could alter red
cell membrane NEFA content. In nystatin-loaded erythrocytes,
intracellular Na and K were 37.4 1.1 and 40.2 4.2 mmol/
liter, respectively. In cells loaded using PCMBS, the final Na
and K concentrations were slightly, but significantly, higher
(46.0 1.7 mmol/liter, Na, and 49.3 2.2 mmol/liter, K; p
< 0.01). Because pump-mediated Rb influx saturates over 30
mmol/liter cell of Nat, these differences should not influence
ouabain-sensitive cation flux rates. In fact, ouabain-sensitive
86Rb influx in cells loaded with either technique (nystatin: 2.6
0.23 vs. PCMBS: 2.9 0.20 PCMBS mmol/liter cells/hr) were
not different. Similarly, there was no difference in furosemide-
sensitive 86Rb influx using either method (0.23 0.02 nystatin
vs. 0.21 0.02 PCMBS mmol/Iiter cells/hr). As the two
techniques yielded similar results, the remainder of the cation
flux experiments in Group 1 patients were performed with the
technically more convenient nystatin method.
In Na-loaded RBCs, maximal Na pump activity (Group 1
patients) did not change significantly with hemodialysis (6.9
5.9% increase, Table 3). Similarly, in fresh cells from Group 2
patients, there was no significant change in ouabain-sensitive
Na efflux rates following dialysis (—4.5 6.4% change, Table
3). However, in Group 2 patients, there was a significant
correlation with changes in intracellular Na occurring with
dialysis and ouabain-sensitive NaF efflux in fresh, nonNa4-
loaded erythrocytes (y = 0.71 x — 2.4; r = 0.59; P < 0.01, N
17).
The effect of dialysis on the activity of Na/K"/Cl cotrans-
port was examined in all Group I patients. There was a small,
but significant, rise in the furosemide-sensitive influx (0.14
0.06 mmol/liter cell/hr, P < 0.02; Table 3). There was no
apparent relationship between intracellular electrolytes (before
or after loading) and Na/K/Cl cotransport maximal activity
in loaded cells, nor was there any correlation between plasma
K and furosemide-sensitive Na efflux in these cells. Mea-
surement of sodium-lithium countertransport in 12 of 34 Group
I patients showed no changes during hemodialysis (Table 3).
Twenty patients in Group I were studied on several occa-
sions over two years. Although in 11 of these subjects, pre-
dialysis ouabain-sensitive Na' efflux rates improved (+ 1.15
0.47 mmollliter cell/hr), there was no significant improvement in
Na pump activity in the group as a whole. There also was no
significant change in Na/K1Cl cotransport over this time.
Effect of dialysis on [3Hjouabain binding
The number of specific [3Hlouabain binding sites was deter-
mined in both Group 1 and Group 2 patients. No significant
change in the number of [3H]ouabain binding sites was induced
by hemodialysis in either group (Table 3), and there was no
correlation between the number of [3H]ouabain binding sites
and the intracellular Na concentration. As expected, there
was a good correlation between maximal ouabain-sensitive Na
efflux in Nat-loaded cells and the number of [3H]ouabain
binding sites in erythrocytes from Group I patients (r = 0.754,
P < 0.001). When data from all Group 1 and 2 patients were
compared to those from 28 ambulatory patients with normal
renal function, there were no differences in either the intracel-
lular Na concentration or the number of (3Hlouabain binding
sites.
Changes in plasma NEFA with dialysis
Plasma concentrations of NEFA were within the normal
range before dialysis (0.57 0.05 mM), and largely consisted of
palmitic, stearic, and oleic acids, with an unsaturated-to-satu-
rated ratio of 0.95 0.09 (Table 4). Post-dialysis and following
the administration of an average dose of 3990 344 units of
heparin, the mean plasma NEFA concentration nearly doubled
(+87%), increasing in 29 of 34 patients (Table 4, Fig. IA). The
ratio of unsaturated-to-saturated NEFA in plasma also signifi-
cantly increased, rising 54% to 1.5 0.09; the largest increases
were due to oleic and linoleic acids. There was no correlation
between the plasma levels of NEFA measured either before or
just after dialysis and cation flux rates, There was also no
relationship between the magnitude of the change in plasma
NEFA with dialysis and any change in RBC cation transport.
Changes in erythrocyte membrane NEFA with dialysis
Erythrocyte membrane NEFA were easily detectable using
the fluorescent derivatizing compound, Br-Mac, and ranged
from 10 to 100 nmol/mg protein. The predominant red cell
membrane NEFA were palmitic and stearic, with a much lower
ratio of unsaturated-to-saturated NEFA than that present in
plasma (Table 4).
In contrast to the rise in plasma NEFA concentration with
dialysis, the concentration of NEFA in RBC membranes fell in
28 of 34 patients; the average decrease was 23% (Table 4, Fig.
IB, P < 0.001). Although the magnitude of the rise in plasma
NEFA did not correlate with the change in RBC membrane
NEFA, all but 8 of the 34 patients with a decline in RBC
membrane NEFA experienced an increase in plasma NEFA.
There was no change in the ratio of unsaturated-to-saturated
NEFA in erythrocyte membranes with dialysis (Table 4), nor
was there any correlation between changes in membrane and
plasma unsaturated-to-saturated NEFA ratios.
There was no apparent relationship between total erythrocyte
Group I
Maximal rates
Na pump activityaNa/K
cotransport"Na/Li
countertransportc
[3H]ouabain binding
Group 2
Fresh cell.cNa pump activitya
(3H}ouabain binding
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Table 4. Plasma and red cell membrane NEFA content changes during hemodialysis
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Plasma
Total NEFA content
iunol/liter
Unsaturated/saturated
NEFA ratio
Erythrocyte membrane
Total NEFA content
nmol/mg protein
Unsaturated/saturated
NEFA ratio
Pre-dialysis
569.9 52.2
0.946 0.090
71.7 8.1
0.383 0.045
Post-dialysis
1063.9 120.1
1.46 0.088
56.1 7.0
0.398 0.038
% Change
86.8 13.2
54.3 2.1
—22.8 3.8
3.9 0.3
<0.001
<0.001
<0.001
NS
Values are mean SEM for 34 patients in Group I. Statistical differences were analyzed by paired Student's 1-test.
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membrane NEFA levels and ouabain-sensitive efflux rates pre-
or post-dialysis. However, when the percent change in eryth-
rocyte membrane NEFA was plotted against the percent
change in Na pump activity, a possible relationship could be
discerned (Fig. 2A). Nine of 11 patients with greater than a 30%
decrease in membrane NEFA had an increase in ouabain-
sensitive efflux, while four of five patients with an increase in
red cell membrane NEFA during dialysis had a decline in Na
pump activity. Indeed, when the percent change in Na activity
was plotted against the log of the percent decline in red cell
NEFA in the 24 of the 34 subjects who had at least a 10%
decrease in membrane NEFA, there was a significant, positive
correlation (r = 0.56, N = 24, P <0.02; Fig. 2B). There was no
significant correlation between changes in red cell membrane
NEFA and changes in either furosemide-sensitive Na efflux
rates, nor in changes in Na/Li countertransport.
In 20 patients randomly chosen from the 34 patients in Group
1, erythrocytes obtained before a dialysis treatment were incu-
bated in fatty acid free albumin, and changes in ouabain-
sensitive cation flux and red cell membrane NEFA levels were
compared to the effects of hemodialysis itself on these same
parameters. Incubation with delipidated albumin resulted in a
15.9 3.5% fall in red cell membrane NEFA content, a value
closely correlated to the decrease in membrane NEFA induced
by dialysis on the same day in the same patients (r = 0.84, P <
0.001; Table 5). Although there was no linear relationship
P
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Pre-dialysis Post-dialysis Pre-dialysis Post-dialysis
Fig. 1. The rise in plasma NEFA with dialysis
in 34 patients in Group I is illustrated in (A).
The percent change averaged 86.813.2% (P
<0.001). In contrast, in (B), RBC membrane
NEFA fell in the same patients by an average
of 23% with hemodialysis (P <0.001, by
paired Student's 1-test).
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10 50 100
Erythrocyte NEFA, log %
Fig. 2. In (A), the percent change in Na" pump activity (ouabain-
sensitive Na efflux) is plo:ted against the percent change in RBC
membrane NEFA. Although there is no significant change in average
Na pump activity with dialysis (Table 3) nor any linear correlation
between the two variables shown in (A), there is a significant correla-
tion when the log of the percent decline in erythrocyte NEFA is plotted
against the percent change in Na" pump activity, as shown in (B) (r =
0.564; P < 0.01) in 24 of the 34 subjects studied who had a decrease in
membrane NEFA content >10%.
between decreases in RBC membrane NEFA content and
changes in sodium pump flux with dialysis, a significant corre-
lation between these two parameters was detected in pre-
dialysis, erythrocytes incubated in albumin (r 0.54, P < 0.05;
Table 5). Interestingly, the changes in ouabain-sensitive cation
flux induced by incubation in delipidated albumin statistically
were related to the changes in ouabain-sensitive cation trans-
port that occurred with dialysis in the same patients (r = 0.47,
P < 0.05; Table 5).
Discussion
We have studied the acute effects of a hemodialysis proce-
dure on erythrocyte cation flux rates in stable hemodialysis
RBC Na
pump
RBC membrane mmol/ Correlation %
NEFA liter cell! iNEFA:%
(,,mo//mg) hr i pump
Pre-dialysis 68.2 7.7 4.08 0.26 —
Post-dialysis 59.1 7.2 4.37 0.29
% Change 13.5 2.8% 4.2 6.0% r=0.41P <0.01 NS NS
Post-albumin 57.4 9.1 4.35 0.31
% Change 15.9 3.5% 6.7 5.9% r=0.54P <0.01 NS <0.05
Correlation r = 0.84
% dialysis:% albumin <0.01
r = 0.47 —
<0.05
P
patients. In agreement with several other reports [3, 4, 7],
erythrocyte Na and K contents were not increased on
average in these patients, nor was there any correlation be-
tween the intracellular Nat content and either the number of
[1H]ouabain binding sites or the maximal ouabain-sensitive
Na efflux rate. Since there was a limited number of patients
studied with a very high erythrocyte Na content, we cannot
exclude the possibility, as suggested by Cheng, Kahn and Kaji
[3], that there is a subset of uremic dialysis patients with high
cell Na' and significantly depressed Na' pump number and
activity.
Compared to rates of ouabain-sensitive Na efflux in eryth-
rocytes from normotensive subjects with normal renal function
as previously reported by us (5.10 0.24 mmol/liter cells/hr,
ouabain-sensitive Na' efflux; N = 21) [29, 301, average active
Nat effiux rates were moderately decreased in RBCs from
patients in the current study. However, Na' pump activity did
not change acutely with hemodialysis whether assayed as
changed in ouabain-sensitive cation flux in fresh cells (Table 3,
Group 2) or at the Vmax of the Na pump in Nat-loaded cells
(Table 3, Group I). Although others have reported a correlation
between weight loss with dialysis and change in active Na
transport [4], we could not confirm this in either group of
patients. There was no relationship as well between changes in
extracellular volume status with dialysis as reflected by weight
loss and changes in Na/K/Cl cotransport activity. How-
ever, as expected, there was a significant correlation between
changes in the intracellular Na content and Na'' pump activity
in fresh cells, indicating that either increases or decreases in
intracellular Na during the dialysis procedure can be of
sufficient magnitude to influence ouabain-sensitive Na effiux
acutely in fresh cells.
Furosemide-sensitive Na/K/Cl cotransport rates were
much lower in the patients we studied than in normal subjects
we have previously reported (normal values for furosemide-
sensitive Na efflux rates of 0.978 0.093 mmol/liter cells/hr,
N = 21) [29, 30], in agreement with evidence from several other
groups [7, 13, 33]. In contrast to the Na pump data, there was
a small, but significant, increase in furosemide-sensitive cotrans-
port rates that occurred acutely with hemodialysis (Table 3,
A
S
Table 5. Changes in red cell membrane NEFA content and NA
pump activity with incubation in delipidated albumin and during
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Group I). As these measurements were performed in pre- and
post-dialysis RBCs loaded to contain the same intracellular
Na and K, and since the osmolality of all solutions was kept
constant, changes in plasma K or red cell volume with dialysis
were unlikely to be the cause of the increase in furosemide-
sensitive Na efflux rates. Finally, in contrast to the reports of
Woods, Parker and Watson [5] and Trevisan et al [6], there
were no changes in maximal red cell Na/Li countertransport
rates with dialysis. This concurs with recent reports by Corry et
al [7] and Smith et al [91.
Thegoal of the present study was to determine whether acute
changes in erythrocyte cation flux rates in end-stage renal
failure patients undergoing a hemodialysis procedure could be
accounted for by acute changes in red cell membrane NEFA
content. NEFA, particularly those with at least one cis-unsat-
urated double bond, are known to affect NaK-ATPase enzyme
activity in broken membrane preparations [21, 34]. The effect is
most likely due to NEFA interactions with the lipid bilayer that
result either in changes in the viscosity of the bilayer as a
whole, or in specific lipid domains adjacent to the enzyme that
are sufficient to alter enzyme conformation. NEFA can also
induce conformational changes in the enzyme sufficient to
inhibit cardiac glycoside binding [20].
The content of NEFA and other polar lipids, such as lyso-
phospholipids, normally does not exceed I to 2 mol percent of
the total phospholipid in the erythrocyte membrane [35]. In
nucleated cells, NEFA that partition into the cell membrane or
arise from the activity of membrane phospholipases are rapidly
converted to acyl CoA derivatives for re-esterification into
phospholipids or triglyceride, or combined with carnitine for
eventual beta-oxidation in mitochondria. In contrast, the red
cell does not have as many metabolic options and may be less
able to respond to rapid changes in plasma NEFA levels or,
perhaps more importantly, to changes in the binding of NEFA
to plasma proteins, principally albumin.
Not surprisingly, total plasma NEFA levels rose significantly
following hemodialysis, in part because of the heparin admin-
istered combined with the abnormal clearance of triglycerides
characteristic of these patients [22, 36]. Artifactually high
NEFA levels have been reported to occur in plasma samples
from patients who have received systemic heparinization due to
continuing activity of activated lipoprotein lipase in vitro fol-
lowing phlebotomy. Although we cannot exclude an effect of
activated lipoprotein lipase on NEFA production in our assay
samples, care was taken to draw venous blood into pre-chilled
tubes, all transfers of plasma were kept on ice, and polar lipids
were extracted in less than one hour following phlebotomy.
Another explanation for the rapid rise in total plasma NEFA
levels during dialysis is that the number of albumin binding sites
available to bind NEFA increased. Albumin, the primary car-
rier of NEFA in plasma, contains a heterogenous assortment of
both high-affinity and low-affinity NEFA binding sites [37].
Albumin normally carries 0.5 to 2.0 mol NEFA per mol of
protein, although much higher mol ratios of NEFA to albumin
have been obtained in vitro [37]. NEFA transfer between
artificial lipid bilayers and albumin occurs rapidly, particularly
if NEFA are in the ionized form, as would occur at physiologic
pH. Occupation of organic acid binding sites on albumin by
accumulated metabolic by-products could result in displace-
ment of NEFA from at least low affinity sites. Removal of
organic acids by dialysis could cause transfer of NEFA from
cell membranes to albumin and result in a rise in total plasma
NEFA levels and a fall in RBC membrane NEFA levels, despite
a heparin-induced increase in lipoprotein lipase activity. This is,
in fact, what we found: RBC membrane NEFA decreased by an
average of 23%, a decline that was highly significant by paired
t-test. In addition, the fall in red cell NEFA content occurring
with dialysis could be mimicked by incubating RBCs obtained
before dialysis with delipidated albumin (Table 5). There was
also a significant correlation between changes in Na pump
activity occurring with hemodialysis, and changes in Na pump
activity occurring during incubation of the same pre-dialysis
erythrocytes with fatty acid-free albumin. These data support
the contention that increased plasma protein binding of NEFA
following dialysis removes NEFA from cell membranes and
contributes to the rise in total plasma NEFA levels.
Although there was no significant change in Na pump-
mediated Na efflux with dialysis in this patient population as a
whole, 24 of the 34 subjects studied had a decrease in erythro-
cyte membrane NEFA content of greater than 10% and in these
patients, there was a significant correlation between the log of
the percent decline in membrane NEFA and the percent change
in maximal Na pump activity (Fig. 2B). Smaller decreases or
increases in membrane NEFA did not have a discernible effect
on ouabain-sensitive Na effiux. These data suggest that if
variations in membrane NEFA content are to have any effect on
the function of membrane proteins, the change must be rela-
tively great.
There are several possible reasons as to why the correlation
between changes in membrane NEFA levels and Na pump
activity is better than that observed here. The first is that there
may be a threshold effect; that is, a relatively large shift of
NEFA out of the membrane (or out of specific membrane
domains) is necessary before any effect on membrane transport
proteins can be detected. Secondly, if lipid-protein interactions
are important in affecting membrane transport proteins, a
relatively high cholesterol:phospholipid ratio in erythrocytes
from some uremic patients may mask or dampen the effect of
alterations in the polar lipid content of membranes [34, 38, 39].
Indeed, cholesterol has been demonstrated to have an indepen-
dent effect on Na pump activity in red cell membranes [40].
Similarly, a reduction in the phospholipid to sphingomyelin
ratio, as has been reported to occur in uremic erythrocytes [41],
will also tend to increase the microviscosity of the membrane.
This would minimize the effect of acute changes in NEFA
content in some patients, and possibly independently modulate
NaK-ATPase activity, as has been reported in cultured myo-
cardial cells [42]. Finally, changes in membrane NEFA content
may not be causally related to changes in NaK-ATPase activity,
but may only be a marker for changes in other polar lipids, such
as lysophospholipids, that are also known to affect membrane
protein function. Nevertheless, the recent demonstration that
L-carnitine dietary supplements can improve ouabain-sensitive
sodium efflux rates in erythrocytes from hemodialysis patients
supports our contention that altered NEFA metabolism plays a
role in abnormal cation flux in uremia [43].
In summary, the evidence presented here supports the pos-
sibility that NEFA, and perhaps other polar lipids, affect active
cation transport rates in uremic erythrocytes. There are very
likely other reasons as well for altered cation flux rates in renal
602 Kelly et al: Membrane NEFA and red cell cation flux in uremia
failure. Further studies are needed to clarify the role of abnor-
mal membrane lipid-protein interactions in the pathophysiology
of uremia.
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